Missing a primary end point in a p2 is a legitimate reason for terminating a partnership. The Amgen termination is still somewhat strange to me though given how early it was cancelled. I agree they saw something, but I'm not sold that it was data that did it. If it is mostly cost issues then that doesn't bode well either...
Fbg, so what you’re are basically saying is Amgen had an early look at data. Which they didn’t like and decided to bail and save themselves from investing/losing anymore money. How is that fair to the rest of the Advaxis investors or legal. If there is any early data that points to trial failure. Shouldn’t we all be made aware of that?
News 
Market Data 
Discover 
